Improved Primary Lung Carcinoma Therapeutics Utilizing a Non-Invasive Approach of Combinatorial Drug Loaded Aerosolized Dry Inhaler Powder

Lung cancer has become an immediate concern and reviewing the side effects associated with conventional chemotherapy, with the advent of nanobiomedicine, various nanoformulations are being researched. In the current study, our team has investigated aerosolized dry inhaler powder loaded with a combination of two potent anti-cancer drugs, cisplatin and paclitaxel for locoregional delivery of the same to the lung tissues. This nanoformulation has been investigated by morphological analysis and in-vitro studies to ensure proper therapeutics. Its efficacy has been determined by the anti-tumor studies. The size of the DPIs have been found to be in the range of 60–85 nm small enough to escape the clearance mechanisms in the pulmonary route. The nanoformulations with size